|
DE1518545A1
(de)
*
|
1965-04-01 |
1970-01-15 |
Boehringer Mannheim Gmbh |
Verfahren zur Herstellung neuer Phenylcyclohexylalkylamine und ihrer Salze
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
EP1677791A4
(en)
|
2003-10-31 |
2007-08-15 |
Takeda Pharmaceutical |
NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
|
|
WO2007015877A2
(en)
|
2005-07-20 |
2007-02-08 |
Kalypsys, Inc. |
Inhibitors of p38 kinase and methods of treating inflammatory disorders
|
|
US20100022637A1
(en)
|
2005-09-29 |
2010-01-28 |
The Trustees Of Columbia University In The City Of New York |
Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
|
|
WO2007126041A1
(ja)
|
2006-04-28 |
2007-11-08 |
Eisai R & D Management Co., Ltd. |
ベンゾイソオキサゾール化合物
|
|
AU2008241490B2
(en)
|
2007-04-16 |
2011-07-21 |
Amgen Inc. |
Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
WO2011163355A1
(en)
|
2010-06-24 |
2011-12-29 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
|
|
SI2688403T1
(sl)
|
2011-03-23 |
2017-08-31 |
Trevena, Inc. |
Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
|
|
WO2013088315A1
(en)
|
2011-12-15 |
2013-06-20 |
Pfizer Limited |
Sulfonamide derivatives
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
WO2015069110A1
(en)
|
2013-11-07 |
2015-05-14 |
Aapa B.V. |
Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
KR20180054826A
(ko)
|
2015-09-24 |
2018-05-24 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
Hiv 성숙 억제 활성을 갖는 화합물
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
KR101825065B1
(ko)
|
2016-05-24 |
2018-02-05 |
한국화학연구원 |
Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201614134D0
(en)
|
2016-08-18 |
2016-10-05 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US11091482B2
(en)
|
2016-08-23 |
2021-08-17 |
Ardelyx, Inc. |
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
|
|
GB2554071A
(en)
|
2016-09-14 |
2018-03-28 |
Univ Dundee |
Small molecules
|
|
WO2018098280A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
CN109422733A
(zh)
|
2017-09-03 |
2019-03-05 |
上海美志医药科技有限公司 |
一类抑制并降解酪氨酸蛋白激酶alk的化合物
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
US20210283261A1
(en)
|
2017-12-05 |
2021-09-16 |
Icahn School Of Medicine At Mount Sinai |
Compositions and Methods for Treating ALK-Mediated Cancer
|
|
CA3085645C
(en)
|
2017-12-13 |
2024-01-16 |
Shanghaitech University |
Alk protein degraders and their use in cancer therapy
|
|
EP3724216A1
(en)
|
2017-12-15 |
2020-10-21 |
Dana Farber Cancer Institute, Inc. |
Stabilized peptide-mediated targeted protein degradation
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
JP7229257B2
(ja)
|
2018-01-29 |
2023-02-28 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|
|
IL302595A
(en)
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
CN110684015A
(zh)
|
2018-07-06 |
2020-01-14 |
四川大学 |
靶向alk的protac及其应用
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
AU2019348006A1
(en)
|
2018-09-27 |
2021-02-18 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target Alk and therapeutic uses thereof
|
|
WO2020114482A1
(zh)
|
2018-12-06 |
2020-06-11 |
中国科学院上海药物研究所 |
一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
|
|
CN111285849A
(zh)
|
2018-12-07 |
2020-06-16 |
上海青东生物科技有限公司 |
一种靶向降解ALK，c-Met和ROS1蛋白的化合物及其制备方法
|
|
WO2020192553A1
(zh)
|
2019-03-22 |
2020-10-01 |
上海海雁医药科技有限公司 |
磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途
|
|
US20230093099A1
(en)
|
2019-04-02 |
2023-03-23 |
Cullgen (Shanghai), Inc. |
Compounds and methods of treating cancers
|
|
WO2020210630A1
(en)
|
2019-04-12 |
2020-10-15 |
C4 Therapeutics, Inc. |
Tricyclic degraders of ikaros and aiolos
|
|
EP4110772A4
(en)
|
2020-02-26 |
2024-04-03 |
Cullgen (Shanghai), Inc. |
TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
|
|
KR102343936B1
(ko)
*
|
2020-02-28 |
2021-12-24 |
전남대학교산학협력단 |
신규한 카르복스아마이드계 화합물 및 이를 포함하는 대사성 질환의 예방 또는 치료용 조성물
|
|
WO2021213929A1
(en)
|
2020-04-20 |
2021-10-28 |
Syngenta Crop Protection Ag |
Pesticidally active substituted 1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives with sulfur containing substituents
|
|
JP7778095B2
(ja)
|
2020-06-24 |
2025-12-01 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
US20230096978A1
(en)
*
|
2020-08-10 |
2023-03-30 |
Chengdu Easton Biopharmaceuticals Co., Ltd. |
Mor receptor agonist compound, preparation method therefor, and use thereof
|
|
CA3194351A1
(en)
|
2020-10-14 |
2022-04-21 |
Christopher G. Nasveschuk |
Tricyclic compounds to degrade neosubstrates for medical therapy
|
|
CN116723839A
(zh)
|
2020-10-14 |
2023-09-08 |
C4医药公司 |
用于降解靶蛋白质的三环杂双官能化合物
|
|
US20240082272A1
(en)
|
2020-12-09 |
2024-03-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating wnt-driven cancer
|
|
TW202530189A
(zh)
*
|
2023-09-29 |
2025-08-01 |
日商第一三共股份有限公司 |
３－苯基丙基胺衍生物
|